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Abstract
Background: The presence of an asymptomatic phase in an HIV infection indicates that the immune system can
partially control the infection. Determining the immune mechanisms that contribute significantly to the partial
control of the infection enhance the HIV infection intervention strategies and is important in vaccine development.
Towards this goal, a discrete time HIV model, which incorporates the life cycle aspects of the virus, the antibody
(humoral) response and the cell-mediated immune response is formulated to determine immune system
components that are most efficient in controlling viral levels. Ecological relationships are used to model the
interplay between the immune system components and the HIV pathogen. Model simulations and transient
elasticity analysis of the viral levels to immune response parameters are used to compare the different immune
mechanisms.
Results: It is shown that cell-mediated immune response is more effective in controlling the viral levels than the
antibody response. Killing of infected cells is shown to be crucial in controlling the viral levels. Our results show a
negative correlation between the antibody response and the viral levels in the early stages of the infection, but we
predicted this immune mechanism to be positively correlated with the viral levels in the late stage of the infection.
A result that suggests lack of relevance of antibody response with infection progression. On the contrary, we
predicted the cell-mediated immune response to be always negatively correlated with viral levels.
Conclusion: Neutralizing antibodies can only control the viral levels in the early days of the HIV infection whereas
cell-mediated immune response is beneficial during all the stages of the infection. This study predicts that vaccine
design efforts should also focus on stimulating killer T cells that target infected cells.
Keywords: HIV immune responses, Elasticity analysis, Discrete time models
Background
The human immune system is a complex network of cells,
chemicals and organs that keeps an individual healthy.
There are three lines of defense that make up the human
immune system. The three types of immunity are, passive
immunity, innate/non-specific immunity and adaptive/
specific immunity. Passive immunity is borrowed from an
external source and lasts for a short time. Innate immunity
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comprises of barriers such as the skin and the mucous
membranes. There are two major branches of the spe-
cific immune responses which are the humoral immune
response and the cell-mediated response. Humoral
immunity is mediated by B cells and cell-mediated immu-
nity involves the production of cytotoxic T-lymphocytes
(CTLs), activated macrophages, activated natural killer
(NK) cells and cytokines in response to an antigen and is
mediated by T-lymphocytes.
Understanding the interactions of these immune sys-
tem mechanisms during an HIV infection is of great
importance in HIV treatment and vaccine development.
However, there are no good animal models for this
infection and mathematical models have been the basic
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tool used to understand these interactions [1-4]. All the
models developed and the related HIV research pointed to
the same conclusion that, although the immune response
poses a tough challenge to HIV infection, the virus
adopts several immune system escape mechanisms. The
virus can escape the immune system through mutations
[5-7], the formation of the viral latent reservoir [8,9] and
through the use of its proteins such as the Vif, Vpu,
Tat [10] and Nef [11]. Treatment regimes were devel-
oped to augment the human immune system in the
fight against HIV infection. However, these treatment
regimes are not easily accessible in developing countries
and hence the need to find a cure or vaccine for the
infection.
In this study, we model the within host dynamics of
the HIV infection using discrete time models because of
their relative simplicity in computing transient elasticities
of viral levels to immune system parameters compared
to ordinary and partial differential equations (ODEs and
PDEs). A discrete time model also allows the incorpo-
ration of all the life cycle aspects of the virus and yet
remain relatively simple to analyse compared to ODEs
and PDEs. The main advantage of transient analysis over
asymptotic analysis is that it focuses on perturbations to
the population structure rather than perturbation analysis
on demographic rates only [12]. Transient elasticity anal-
ysis is also effective in analyzing the effects of changes of
parameters and initial conditions on population levels in
the short term.
Ecological modelling tools are employed to model the
interplay between the immune system and the HIV
pathogen. The human immune system is treated as an
ecosystem and the components of the immune system
are treated as species in that ecosystem. Pathogens, in
this case, HIV, are then defined as exotic species, which
can either invade the ecosystem or be driven to extinc-
tion. In an ecosystem, all organisms are connected by
ecological relationships namely predation, competition,
mutualism, commensalism, amensalism and parasitism.
Such relationships are comparable to the human immune
system. In the human immune system, examples of such
relationships include CTLs hunting and killing infected
cells, antibodies neutralizing viruses, one strain of HIV
competing for CD4+ T cells, two or more HIV strains
competing for CD4+ T cells, CD4+ T cells offering a cat-
alytic effect to both the B cells and the CD8+ T cells
and immune surveillance, where different components
of the immune system interact to maintain homeosta-
sis. Transient elasticity analysis is then used to compare
the two arms of the specific immune response and hence
inform on HIV vaccine or treatment development. Elas-
ticity analysis can be defined as a method of evaluating
how proportional changes in model parameters affect the
population growth. Parameters with high absolute values
of elasticities are predicted to give greatest changes in
population levels when altered by a fixed quantity, thereby
predicting good targets for the control. In this study, the
immune response in which these parameters are found, is
the immune response that is predicted to be most effective
in controlling the viral levels.
Results
Model simulations
Numerical simulations are performed to show the dynam-
ics of HIV infection under different immune response
mechanisms. These simulations are performed in order
to identify the specific immune system component that
is most effective in controlling the HIV infection. Each
immune response mechanism is considered separately by
setting all the other immune response mechanisms to
zero, except the ones under consideration. For instance,
to consider the chemokine antiviral response which work
by reducing the infectivity of the virus, the expressions
labeled antibody, lytic and cytokine are set to 1 in the
model which include specific immune responses (sys-
tem of equations (7)-(14)). This model (with chemokine
response only) is called the chemokine response model
in this study. The model with non zero immune sys-
tem parameters is referred to as the combined model.
The basic model is the resulting model after all the
immune system parameters are set to zero (the system of
equations (1)-(6)). The function of the basic model is to
act as a control, in the sense that it gives the viral, infected
and uninfected cell levels, before the intervention of the
immune system.
We carried out literature search to obtain parameters
we used to carry out simulations. Where we could not
find parameters values, we used values that could gen-
erate acceptable HIV dynamics. The parameter value for
β1 was obtained from [13] and a description of how this
parameter value was computed is also given [13]. It was
found by a study in [14] that the infectivity of the cell
associated virus is 102 to 103 times greater than the infec-
tivity of free virus stocks so we multiplied the infectivity
of the free virus by values in the ranges 102 to 103 to
get the infectivity of the cell-associated virus β2. However,
this range is from an in vitro model. In order to find the
form of transmission that is more efficient in the blood
and support the use of the values obtained from an in
vitro model, we conducted a study using our mathematical
models to find the form of transmission that is more effi-
cient in vivo. Results showed that cell-to-cell transmission
was efficient in transmitting the infection than cell-free
transmission, a result consistent with in vitro models
[15-17]. Part of the results of this study are given in
Additional file 1. A comprehensive sensitivity analysis of
immune response parameters is performed in the elastic-
ity analysis section. Sensitivity analysis of the viral levels to
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the viral life cycle parameters is added in Additional file 1.
The parameter values used for simulations are given in
Table 1.
Numerical simulations of the viral levels against time
under the different immune response models are shown
in Figure 1.
Simulations of models with immune responses resulted
in reduced viral levels, though the reduction was high
when all the immune system’s antiviral responses were
combined. The chemokine immune response model pre-
dicted viral levels that are comparable to those of the basic
model. The graph of the chemokine immune response
model was so close to that of the basic model so that
they appeared as overlapping graphs and was therefore
omitted. We can therefore predict that chemokines are
Table 1 Parameter values
Parameter Description Value Source
β1 Virus infectivity 0.000024 ml−1d−1 [13]
β2 Cell-associated 100 − 1000× [14,15,17]








μT Death rate of CD4+ T
cells
0.02 d−1 [18]
ω Saturation constant 0.01 ml−1 Est.
ST Source term for
CD4+ T cells
10 cells d−1 Est.
μC CTL death rate 0.5 d−1 Est.
μT∗ Infected cell death
rate
0.5 to 1 d−1 [18]
μB B cell death rate 0.5 d−1 Est.
θ1 Transition probability 1/3 [19]
θ2 Transition Probability 0.06315 Computed








proliferation of B cells
0.01 Est.
a1 Saturating constant 0.002 ml−1 Est.
a2 Saturating constant 0.002 ml−1 Est.
Parameters values that were not obtained from literature were chosen to be in
the ranges 0 to 1. Est. means parameters were estimated/derived to simulate
acceptable HIV dynamics. The infectivity of the cell associated virus is 102 to 103
times greater than the infectivity of free virus stocks [14], so we multiplied the
infectivity of the free virus by values in the ranges 102 to 103 to get the
infectivity of the cell associated virus.























Figure 1 Plots of viral levels against time under different
immune response models. Neutralizing antibodies are not very
efficient in controlling viral levels. The antibody response model
yielded levels that settled to levels comparable to those of the basic
model (model without immune system intervention). Lowest viral
levels are obtained when all the specific immune system
components work simultaneously as is shown by the graph of the
combined model. Killing of infected cells also play a very crucial role
in reducing the viral levels as can be seen from the graph of the lytic
model. The parameter values used are given in Table 1 and the initial
conditions were D0 = 100, P0 = 100, Q0 = 100, V0 = 100, T0 =
750, T∗0 = 100, C0 = 1, B0 = 1.
not efficient in controlling viral levels. During the early
days of the infection, the reduction in viral levels due to
the neutralizing antibody response model was comparable
to that of the combined response model, however as the
infection progresses, it became comparable to the basic
model. This result suggests that neutralizing antibodies
reduce the viral levels significantly in the acute stage of
this infection and that their role diminishes with infec-
tion progression. It can also be seen from Figure 1 that
lysing of infected cells is critical in controlling the viral
levels.
Simulations of uninfected CD4+ T cell levels under the
different immune response models are shown in Figure 2,
in which uninfected CD4+ T cells are demonstrated to
increase, with the highest increase achieved with the com-
bined immune response model.
From Figure 2, it can be observed that the role of the
antibody response in maintaining high uninfected cell
levels is more defined during the early days of the infec-
tion than during the later days of the infection. The
cytokine and the chemokine responses are not effective in
maintaining high uninfected cell levels. The graph of the
chemokine response model coincided with the graph of
the basic model. It can also be seen that the lytic antivi-
ral response play a significant role in maintaining high
uninfected cell levels.
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Figure 2 Plots of uninfected CD4+ T cell levels against time
under different immune response models. All immune response
models predict increased uninfected CD4+ T cell levels, with the
highest increase predicted from the combined model. Cytokines and
chemokines are inefficient in maintaining high uninfected cell levels.
The graphs of the cytokine and chemokine models are shown to settle
to values close to those of the basic model. The parameter values used
are given in Table 1 and the initial conditions were D0 = 100, P0 =
100, Q0 = 100, V0 = 100, T0 = 750, T∗0 = 100, C0 = 1, B0 = 1.
Figure 3 shows infected cell levels obtained from differ-
ent immune response models. The cytokine and antibody
models settled to levels comparable to those of the basic
model, though the levels are slightly higher than those
from the basic model. The lytic antiviral response model
resulted in the lowest infected cell levels. The combined




























Figure 3 An illustration of simulated infected CD4+ T cell levels
with different immune response models. Infected CD4+ T cell
levels from the cytokine and neutralizing antibody models settle to
levels that are comparable to those of the basic model (a model
without immune system intervention). The parameter values used are
given in Table 1 and the initial conditions were D0 = 100, P0 =
100, Q0 = 100, V0 = 100, T0 = 750, T∗0 = 100, C0 = 1, B0 = 1.
models predicts infected cell levels that are comparable to
those of the lytic response.
The viral, infected and uninfected cell levels show an
oscillatory behavior even if the time (t) is increased to 200.
This is a common feature of the predator-prey models that
we have used.
Elasticity analysis
Transient elasticity analysis of the viral level to immune
system response parameters which is another way of per-
forming sensitivity analysis was done using the methods
suggested in [20], to substantiate and clearly demon-
strate the influence of immune response parameters on
viral levels. The sensitivity of the viral level to immune
response parameters is given by dV (t)dθ ′ and the elastic-
ity of the viral level to immune response parameters is
given by θV (t)
dV (t)
dθ ′ , where θ is a vector containing the
immune response parameters. The derivation of this for-
mula is given in Additional file 2. A negative elasticity
value means that there is an inverse relationship and a
positive elasticity means that there is positive correlation.
Elasticity values at time point 10 and time point 30 are
given in Figure 4. The graphs show that the elasticities of
the viral levels to immune response parameters are time
dependent.
In Figure 5, we give the transient elasticity values over
200 time points.
It was observed that during the early days of the infec-
tion the viral level was most elastic to the probability of
proliferation of B cells ψ , followed by h1, the neutralizing
efficiency of antibodies. Since these elasticity values are
negative, it means that if the probability of proliferation
of B cells and the neutralizing efficiency of antibodies are
increased as soon as the virus is introduced, lower viral
levels will be obtained. Since these two parameters are
from the neutralizing antibody response, it means that the
neutralizing antibody response is more effective in con-
trolling the viral levels than any other specific immune
component during the early days of the infection. How-
ever, as time progressed, the viral level was most elastic
to the lytic antiviral response parameter h2, followed by
the probability of proliferation of CTLs, χ and was least
elastic to h, the cytokine antiviral response parameter.
This means that killing of infected cells is most effec-
tive in controlling the viral levels as soon as the infection
become established, followed by the probability of prolif-
eration of these CTLs. The elasticities of the viral level
to the antibody response parameters changed from neg-
ative to positive as time progressed and these positive
values are very close to zero. Thus we can predict that
neutralizing antibodies are only efficient in reducing the
viral levels in the early days of the infection and that
increasing antibody response parameters once the infec-
tion become established will result in elevated viral levels.
Showa et al. BMC Research Notes 2014, 7:737 Page 5 of 18
http://www.biomedcentral.com/1756-0500/7/737
Figure 4 Elasticities of the viral levels to immune response parameters. a, gives the elasticities plot at time 10. Increases in all parameter values
result in reduced viral levels. However the chemokine antiviral response which is represented by the parameter h, does not significantly contribute
to the control of viral levels. Parameters from the antibody response (h1, ψ ), are predicted to be the best targets for the viral level control. b, gives
the elasticities plot at time 30. Parameters from the antibody response have positive elasticity values and thus their increases result in increased viral
levels. The lytic antiviral response is predicted to be the best target for the control of viral levels. The parameter values used are given in Table 1 and
the initial conditions were D0 = 100, P0 = 100, Q0 = 100, V0 = 100, T0 = 750, T∗0 = 100, C0 = 1, B0 = 1.
Elasticity analysis of the viral levels to immune response
parameters predicted results that were also obtained by
model simulations (see Figure 1). Elasticity analysis of
the viral levels to other model parameters is given in
Additional file 1.





















Figure 5 Transient elasticities of the virus population with
respect to immune system parameters. During the early days of the
infection the viral level is more elastic to the neutralizing antibody
response parameters but as the infection progresses the viral levels are
more elastic to the cell-mediated response parameters. The elasticities
of the viral level to the antibody response parameters changed from
negative to positive as time progressed. Thus we can conclude that
neutralizing antibodies are only efficient in controlling the viral levels
in the early days of the infection. The parameter values used are given
in Table 1 and the initial conditions were D0 =100, P0 = 100, Q0 = 100,
V0 = 100, T0 = 750, T∗0 = 100, C0 = 1, B0 = 1.
Correlations of the viral levels to the immune system
components predicted to be efficient in controlling the
viral levels
Results from previous sections show that neutralizing
antibodies are only efficient in reducing the viral levels
during the early days of the infection and that as time pro-
gresses their role changes from decreasing the viral levels
to be positively correlated with the viral levels. To visual-
ize these results, we fixed a time point in the early days of
the infection and a time point in the late days of the infec-
tion then vary the parameters ψ and h1 and plot the viral
levels against these parameter ranges in Figure 6.
At time 10, we observed a negative correlation between
h1, the neutralizing efficiency of antibodies and viral
levels, and between the probability of proliferation of B
cells and viral levels. At time point 100, it can be seen that
as the values of h1 and ψ increase, the viral levels also
increase. The scatter plots clearly show that the role of
antibody (humoral) response depends on the stage of the
infection.
We also observed that the viral levels were most elastic
to h2, the killing efficiency of CTLs during the late days
of the infection and that the effect of this parameter was
not dependent on the stage of the infection (all the elas-
ticity values were negative in Figure 5). This means that
an inverse relationship will be observed at all the stages
of the infection. We randomly picked time point 100, to
generate the scatter plot in Figure 7. The scatter plot in
Figure 7 shows that there is a negative correlation between
the killing efficiency h2 and the viral levels. We expect the
same relationship at all time points.
Showa et al. BMC Research Notes 2014, 7:737 Page 6 of 18
http://www.biomedcentral.com/1756-0500/7/737
Figure 6 Scatter plots with model fits between the viral levels and immune response parameters. a and b give the scatter plots with linear
fits between the viral levels and the neutralizing efficiency h1 of antibodies at time t = 10 and t = 100, respectively. The circles are the data points
and the line is the linear fit. In Figure 6a, a negative relationship between the viral levels and the antibody neutralizing efficiency is observed.
Figure 6b shows a positive relationship between the viral levels and the neutralizing efficiency. c-d give scatter plots with linear fits (correlations)
between the viral levels and the probability of proliferation of B cells ψ , at time t = 10 and t = 100, respectively. Figure 6c shows a negative
relationship between the viral levels and the probability of proliferation of B cells. In Figure 6d, a positive relationship between the viral levels
and the probability of proliferation of B cells is observed. The parameter values used are given in Table 1 and the initial conditions were
D0 = 100, P0 = 100, Q0 = 100, V0 = 100, T0 = 750, T∗0 = 100, C0 = 1, B0 = 1.
Effects of transmission parameters on viral levels
We varied the parameters β1 and β2, to see their effects on
viral levels and the results are shown in Figure 8.
We observed that the viral levels increase with increases
in β1 and β2. However, increasing β2 had a greater impact
on viral levels when compared to increases in β1, and thus
we can conclude that the viral levels are more sensitive to
β2 than β1. When these two parameters were increased
simultaneously, after an initial increase, the viral levels will
start to decrease with increases in these two parameters.
Theoretically, these results imply that the transmission
parameters are bifurcation parameters. Increases above
certain thresh hold values will impact negatively on viral
levels.
Discussion
Discrete time HIV models that incorporate the life cycle
aspects of the virus, the antibody (humoral) response
and the T-cell response were formulated to determine
immune system components that are most efficient in
controlling viral levels. The interplay between the immune
system components and the virus at the different stages
of its life cycle was modelled using ecological relation-
ships. The flexibility of the developed models allowed
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Figure 7 Scatter plots with a quadratic fit between the viral
levels and the infected cell killing efficiency of CTLs. The red line
represent the quadratic fit and the small circles represent the data
points (model outcomes). There is a negative relationship which can
be best be explained by a quadratic function between the viral levels
and the killing efficiency of infected cells by CTLs. The parameter
values used are given in Table 1 and the initial conditions were
D0 = 100, P0 = 100, Q0 = 100, V0 = 100, T0 = 750, T∗0 = 100,
C0 = 1, B0 = 1.
an in-depth examination of the interactions between the
specific immune system’s antiviral response and the HIV
pathogen.
Neutralizing antibodies were predicted to be effective in
controlling viral levels in the early days of the infection,
a result observed in several experimental studies [21-25].
However, neutralizing antibodies were not able to control
the viral levels once the infection become established as
was observed in the studies [26,27]. The reason for this
could be the fact that antibodies (HIV predators) neu-
tralize free virus (prey) thereby reducing the parasitoid
(HIV) pressure on the host (CD4+ T cells). This will allow
the host population to grow. Reduced levels of free virus
means less stimuli and hence reduced levels of B cells. The
virus population will then start to grow (due to increased
levels of CD4+ T cells) with two advantages; first, more
CD4+ T cells (host) and second, less B cells (predator).
Increases in viral levels are at the expense of CD4+ T cell
levels. When the B cells start to increase due to increased
viral levels (prey), they do so with a disadvantage of
low CD4+ T cell levels and hence their proliferation is
impaired. It is also important to note that neutralizing
antibodies target the early stage of the HIV life cycle, a
stage at which viral levels were shown to be least sensitive
to [28-30]. Currently there is no information besides the
high viral mutation rates, that explain why neutralizing
antibodies fail to control the infection. This result provide
this understanding and prediction that could be critical








































































Figure 8 Effects of the transmission parameters on viral levels.
The plots gives natural log of the viral levels against time. a gives the
plots for viral levels when β1 and β2 are varied simultaneously, b
gives the plots for viral levels when β2 is varied and c gives the plots
for viral levels when β1 is varied. The viral level increases with
increases in β1 and β2, however, increasing β2 had a greater impact
on viral levels when compared to increases β1. The viral levels are
more sensitive to β2 than β1.
Showa et al. BMC Research Notes 2014, 7:737 Page 8 of 18
http://www.biomedcentral.com/1756-0500/7/737
in the knowledge required for the designing of effective
antibody based vaccines.
The chemokine response model predicted viral levels
which settled to the same levels as those of the basic
model (a model without immune system intervention that
was used as a control). The reason for this could be
that, chemokines target the early stages of the HIV life
cycle and hence are not effective in controlling viral lev-
els. The lytic antiviral response was predicted to be most
effective in controlling the viral levels amongst the three
cell-mediated immune responses considered in this study.
A model which combines the neutralizing antibody
and cell-mediated immune responses on HIV infection
dynamics was also considered. This model demonstrates
increased levels of uninfected CD4+ T cells and reduced
viral and infected cell levels. This may have come as a
result of the fact that the presence of neutralizing antibod-
ies increases the CD4+ T cell levels and thereby improving
the CTL antiviral response.
Transient elasticity analysis of the viral level to the
immune system’s antiviral response parameters was per-
formed. It was observed that during the early days of the
infection the viral level was more elastic to neutralizing
antibody response parameters than the cell-mediated
response parameters, thus increasing the neutralizing
antibody response parameters at the sites of HIV entry
may circumvent the infection better than the T cell
response parameters. This result is logical given the
fact that T cell based immune response is elicited by
infected cells thus they will have to work when the infec-
tion become established. However, it should be noted
that although the neutralizing antibody effect resulted in
reduced viral levels in the early days of the acute phase,
this was at the expense of increased infected cell levels.
The elasticities of the viral levels to neutralizing antibody
response parameters changed from negative to positive
after a few time points. Thus their effect as the disease
progresses will change from decreasing the viral levels to
increasing the viral levels. From this study we can pre-
dict that cell-mediated immune response cannot protect
against infectious challenge but can control an established
infection whereas the neutralizing antibody response can
protect against challenge but can not control established
infections.
The elasticities of the viral levels to the cell-mediated
immune response parameters are negative for all time
points. This result agrees with experimental results that
CTLs are effective at all stages of the infection from
the acute phase [31-34] to the late days of the infection
[35,36]. We therefore predict that cell-mediated immune
response is more effective in controlling the viral levels
than the neutralizing antibody response. This result is
consistent with experimental results [37-40]. Amongst the
four specific immune response components considered
(neutralizing antibody, CTLs’ chemokines, cytokine and
lytic responses), we found that the CTLs’ lytic antiviral
response was most effective in reducing the viral levels.
However, from the model structure, it seems that this
conclusion is mainly because it is assumed that neutral-
izing antibodies and chemokine responses do not prevent
cell-to-cell spread of HIV at all. Nevertheless, if we were
to assume that neutralizing antibodies and chemokines
inhibit cell-to-cell transmission thereby reducing the
transmission parameter β2, we will still find that these
responses’ effect on viral levels will still be lower than that
from the lytic response as these immune responses will be
targeting the early stages of the viral life cycle, stages in
which it was shown by several studies that the viral levels
are least sensitive to [41-44].
Sensitivity analysis of the viral levels to other model
parameters was done and details are in Additional file 1.
It was shown that the viral levels are most elastic to φ fol-
lowed by θ2 and least elastic to β1. The implication for this
result is that the viral levels are most sensitive to viral pro-
duction per cell per unit time and least sensitive to the rate
at which cells are infected by cell free virus.
Although our model provide predictions that can be
used to inform on HIV vaccine and treatment develop-
ment, it did not include all the specific immune responses
such as the antibody-dependent-cellular-cytotoxicity
(ADCC) and antibody-depended-cell-mediated-virus-
inhibition (ADCVI). Including these antibody effector
mechanisms may bring more insights on the role of
antibodies in an HIV infection. Moreover, most of HIV
replication occurs in the lymph nodes and the lymphatic
tissues and not in the blood. In this study replication in
the blood was considered, with the hope that if replication
in the blood is reduced then the livelihoods of infected
persons will improve just as is the case of HIV treatment.
Antiretroviral therapy can reduce the HIV viral levels to
undetectable levels in the peripheral blood but its effect
on the lymphoid tissue is very limited as predicted by
failure by most drugs to penetrate the lymphoid tissue
and stop the ongoing replication in these tissues [45].
However antiretroviral therapy improve the livelihoods of
infected persons despite this loop hole.
HIV-infected cells continue to make viruses in lymphoid
tissues even if an individual is under treatment and having
undetectable viral levels in the blood [45]. If HIV replica-
tion in these tissues can be stopped then HIV can be cured
[46]. Modelling HIV replication in the lymphoid tissue will
help identify an immune response that is most efficient in
controlling replication in this site where the bulk of HIV
replication and pathogenesis occurs and this finding may
have many potential implications for the future of HIV
therapy and for attempts to try and cure HIV infection but
is however impeded by lack of data in this compartment.
In humans, blood is commonly monitored to measure
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disease progression and assess immune status and hence
infection parameters in blood are readily available than in
tissues.
Conclusion
The CTLs’ lytic antiviral response was predicted to be
the most effective in reducing the viral levels during all
stages of the infection. It was also observed that the killing
of infected cells plays a very significant role in increas-
ing the uninfected cell levels and decreasing the infected
cell levels. We therefore predict that concentrating on
antibody-dependent-cell-mediating cytotoxicity may be
more beneficial in the control of the HIV infection than
focussing on neutralizing antibodies only. Another strik-
ing result that was observed was that, the effect of neutral-
izing antibodies on viral levels is depended on the stage of
the infection.
Methods
In this section we develop our models: (i) the basic model
considers the interaction between the virus and CD4+ T
cells (ii) the specific immune response model is an exten-
sion of the basic model that includes the specific immune
responses. The models represent cell interaction in the
blood compartment where perfect mixing of cells and the
virus is assumed. Age structure of infected cells maybe
added to the model to get a system of integrodifference
equations in the case where age is a continuous variable
or a discrete multi-state model in the event where age
is discrete. Segregating infected cells by age of infection
may bring useful insights but at the expense of a com-
plex model which might be difficult to analyze and may
hence fail to meet the objectives of this study. We there-
fore ignored the age structure of infected cells and assume
that infected cells are indistinguishable from each other.
The basic model
The stages in the HIV replication cycle are; receptor bind-
ing, cell entry, uncoating, reverse transcription of viral
RNA into DNA, nuclear entry, integration of the viral
DNA into the host DNA and transcription and translation
of viral RNA, assembly of virus progeny particles and bud-
ding. Receptor binding, cell entry, uncoating and reverse
transcription of viral RNA into DNA are combined into a
single stage, HIV-DNA stage, (D). Nuclear entry and inte-
gration of the viral DNA into the host DNA are combined
into the provirus stage, (P). Transcription, translation of
viral RNAs and assembly of virus progeny particles are
combined to yield the virus progeny. Here, it is assumed
that all the virus progeny will mature and thus mature
virus production per infected cell per replication cycle is
equated to the progeny virion production per replication
cycle. This type of stage classification is motivated by the
following facts:
• Treatment of HIV/AIDS available targets the virus at
these stages,
• The immune system also targets the virus at these
same stages [47-49].
• The transition probabilities (proportions that move
from one stage to the next stage) at these stages are
well defined [50-53].
The duration of the DNA stage is 0.5 days [54] and
the provirus stage takes variable time mainly because of
the complex nature of the mechanisms involved in the
processes of transcription and translation, and the highly
probabilistic nature of these processes. We approximate
the provirus stage duration by a Negative Binomial Dis-
tribution, as illustrated by [55], the details are given in
Additional file 2. This resulted in two pseudo-provirus
stages with transition probability θ2 = 0.5 and the prob-
ability that the provirus will survive and remain in the
same pseudo provirus stage θ3 = 0.43685. We let Dt be
the population (level) of viral DNAs, Pt be the provirus
population in the pseudo provirus stage 1, Qt be the
provirus population in the pseudo provirus stage 2, Vt be
the virus population (viral level), Tt be the CD4+ T cell
population (level) and T∗t be the infected cell population
(level). HIV is transmitted through cell free diffusion and
cell-to-cell transfer [56,57], the later being a significantly
more efficient mode of transmission [14,15,58]. The rela-
tionships between a healthy CD4+ T cell and the virus
and between an infected cell and a healthy CD4+ T cell
are modelled using host-parasitoid interactions (Poisson
probability distribution) with a slight modification that
in host-parasitoid models, there is an assumption that
once the host is parasitized (CD4+ T cell is infected), it
is functionally dead until the parasitoid (virus) ‘offspring’
emerge from it. In an HIV infection, there is a time delay
before death actually occurs. This results in a mixed pop-
ulation of infected (unparasitised) and uninfected cells
(parasitised). The average number of virus attached to
a CD4+ T cell is given by β1Vt + β2T∗t . It is assumed
that all the virus that manage to attach to the cell will
undergo the process of fusion and transcription so that
β1Vt + β2T∗t represents the amount of viral DNA that
enter the cell per time step. It has also been observed that
almost all HIV linear unintegrated DNA are rapidly trans-
ported to the nucleus where they are either processed into
two types of cycles or integrated [50]. Only those that
are integrated are involved in the HIV replication cycle
[59]. Those that circularize can be available at the next
time step, but are assumed to be no longer participating
in the replication cycle and are therefore are left out in
the model. Thus if D does not integrate and become P at
time t, it is assumed that it will not be available at time
t +1.The time step for the model is 0.5 days, time spend in
the DNA stage. The stage structured model for HIV, with-
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out the intervention of immune components, takes the
form
Dt+1 = β1Vt + β2T∗t , (1)
Pt+1 = θ1Dt + θ3Pt , (2)
Qt+1 = θ2Pt + θ3Qt , (3)
Vt+1 = θ2φQtT∗t , (4)
Tt+1 = ST + νTt exp









1 − exp[−(β1Vt + β2T∗t )])
+ (1 − μT∗)T∗t . (6)
This model is referred to as the basic model in the rest
of the manuscript. Equation (2) represents the amount of
provirus in the first pseudo provirus stage. The propor-
tion of the DNA that survive and grow from the D stage
to the P stage is given by θ1 and the proportion of the
provirus that survive and remain in the P stage is given
by θ3. Equation (3) represents the second pseudo provi-
ral stage. The proportion of the provirus that survive and
grow from the P to the V stage is given by θ2, and θ3 is
the proportion of the provirus that survive and remain in
the Q stage. Equation (4) is the equation of the mature
virus population, φ represents the number of virus par-
ticles produced per provirus per replication cycle. Viral
production depends on the density of the infected CD4+
T cells. The parameter θ2 represents the transition prob-
ability from the provirus stage to the virus stage. The
same parameters θ2 and θ3 were used in equations (2)-(4)
because the pseudo stages are assumed to be identical, so
the transition and survival probabilities in these stages are
the same. We have assumed that the viral level (density)
at time t + 1, does not depend on the viral level at time
t, because plasma virus have a mean life span of 0.3 days
[60] and the time step for the model is 0.5 days, mean-
ing that no plasma virus is able to survive to the next time
step.
Equations (1)-(3) give the intracellular equations of the
virus life cycle. The quantities give the levels per cell and
to get the total quantities per ml of blood, we multiply
the intracellular levels by the number of infected cells per
ml, T∗t . Equation (4) gives the extracellular equation of the
viral life cycle. The expression θ2φQt gives the viral pro-
duction per cell so that θ2φQtT∗t gives the levels per ml of
blood. The life cycle graph of the virus showing the inter-
action of the intracellular and extracellular events is given
in Figure 9.
Death of infected cells is modelled through the param-
eter μ∗T . Through this parameter, the intracellular steps
associated with the dying cells are flashed out of the sys-
tem when death of infected cells occurs. For this reason
we keep track of the remaining infected cells by the term(
1 − μ∗T
)
T∗t , which is then considered in the intracellular
compartment. If one is to kill all infected cells, at time t,
there will be zero populations at the intracellular stages at
time t since the intracellular levels will be multiplied by
zero to get the levels per ml.
Equation (5) models the number of CD4+ T cells at
time t + 1, ST is the constant supply from the thy-
mus which is assumed to occur at the beginning of the
time step and ν = 1 − μT , where μT is the propor-
tion of uninfected cells that die per time step. Death is
assumed to occur at the end of the time step so that
1 − μT , gives the proportion of uninfected cells that
survive per time step. Uninfected cells must survive infec-
tion by infected cells and the virus for them to remain
healthy. We have assumed that a CD4+ T cell can be
infected by free virus particles or by cell associated virus
through contacts of infected cells and uninfected cells in
a random fashion (contacts are assumed to be randomly
distributed). The proportion of cells that survive infection
per time step is given by exp
(−β1Vt − β2T∗t ). The last
term in the equation represents the proliferation of CD4+
T cells and the expression was adopted from [61]. Prolif-
eration is assumed to occur at the beginning of the time
step.
Equation (6) is the equation for infected cells and μT∗ is
the probability that the infected cell dies naturally. Death
is assumed to occur at the end of the time step, so that
1 − μT∗ is the proportion of infected cells that survive
per time step. The first term on the right hand side of
equation (6), gives the gain term due to infection of CD4+
T cells. The expression 1 − exp(−(β1Vt + β2T∗t )), rep-
resents the proportion of uninfected cells that become
infected per time step.
Modelling the specific immune response
The immune system fight HIV using several mechanisms.
The humoral (neutralizing antibody) response neutralize
free virus, thereby reducing the amount of free virus that
can attach to and infect the CD4+ T cells [62]. Antibodies
are not cells but molecules secreted by the B cells and each
B cell secrete a unique antibody. Cell-mediated immu-
nity involves the production of cytotoxic T-lymphocytes
(CTLs). CTLs either release substances which kill the
infected cells through a process called lysis [63] or secrete
cytokines that trigger a reaction inside the infected cells
that prevents the viral genome from being expressed
[64,65] and/or chemokines that inhibit viral entry into
cells [66]. The lysing of infected cells will be referred to as
the lytic antiviral response and the mechanism of secret-
ing cytokines to counter the infection will be referred to
as the cytokine antiviral response and the mechanism of
Showa et al. BMC Research Notes 2014, 7:737 Page 11 of 18
http://www.biomedcentral.com/1756-0500/7/737
Figure 9 The life cycle graph for HIV showing the intracellular and the extracellular stages of the virus life cycle. The provirus stage P, has
been broken down into two pseudo stages, P and Q. The provirus stage duration distribution is approximated by a Negative Binomial Distribution.
secreting chemokines will be referred to as the chemokine
antiviral response in the subsequent sections. The model
which includes specific immune responses takes the form.




Vt + β2T∗t , (7)
Pt+1 = θ1Dt + θ3Pt , (8)
Qt+1 = θ2 exp(−hCt)︸ ︷︷ ︸
cytokines
Pt + θ3Qt , (9)
Vt+1 = θ2φQtT∗t , (10)
Tt+1 = ST + νTt exp
(
−β1Vt exp(−h1Bt)



















× exp(−h2Ct)︸ ︷︷ ︸
lytic




Ct+1 = f (Tt)T∗t
[
1 − exp(−h2Ct)




] + (1 − μB)Bt . (14)
We have assumed a predator prey relationship where
there is a hunt and kill relationship such as neutralizing
antibodies eliminating/killing virus particles, CTLs hunt-
ing and killing the infected cells. In such relationships
there is an exponential decay of the prey and an exponen-
tial increase in the predator therefore the primary reason
for the exponential term selection. However we opted for
a saturating type term in the case of an immune mech-
anism function depending on the amount (density/level)
of specific cytokines or chemokines or a hybrid of satura-
tion term in an exponential term in which case the decay
depends on the density of the biological variables. For
example, chemokines inhibit viral replication by block-
ing the critical interaction between coreceptors and the
V3 domain of the viral envelope glycoprotein gp120 [66].
The infectivity of the virus is related to the number of
envelope glycoproteins on its surface [67], so we assumed
that the relationship is saturating because as soon as
all the glycoproteins are interfered with, increasing the
chemokines will not have any impact. The model is built
on the assumption that the higher the levels of CTLs
secreting these chemokines, the lower the infectivity of
the virus. In the presence of the chemokine secreting
CTLs (chemokine immune response), a virus infectivity
function of the form β11+ωCt , is assumed, where ω is a satu-
ration constant. The function 11+ωCt → 0 as Ct → ∞ and
1
1+ωCt → 1 as Ct → 0.
The interaction of the HIV antigen and the antibodies
is similar to predation with a modification that prolifera-
tion (population growth function) of B cells is dependent
on helper T cells. We thus model the interaction between
neutralizing antibodies and HIV using a predator-prey
relationship. We further assume that the levels of circulat-
ing antibodies is proportional to the levels of B cells. The
first term on the right hand side of equation (7) is multi-
plied by exp(−h1Bt), where h1 is the antibody neutralizing
efficiency, to cater for the neutralizing effect of antibodies
(predator effect), as Bt → ∞, exp(−h1Bt) → 0. It should
also be noted that as Bt → 0, exp(−h1Bt) → 1. The
expression β2T∗t represents HIV genome entry through
cell to cell contacts. Cell-to-cell eliminates the rate lim-
iting step of diffusion, thereby reducing the exposure
time of viral particles to neutralizing antibodies and
chemokines. There are conflicting reports with regards to
the efficiency of antiviral responses such as neutralizing
antibodies and chemokines in inhibiting cell-to-cell trans-
mission [68-72]. In this study, we assume that cell-to-cell
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transmission is not affected by the extracellular environ-
ment, antibodies and the chemokine immune response in
this case.
Cytokines have been reported to inhibit the viral life
cycle at the transcription level [64,65], by targeting early
proviral gene expression [73]. We therefore assume that
these cytokines affect the transition probability from the
first pseudo provirus stage to the second pseudo provirus
stage (Q). It is still unclear how the CD8+ T cells specifi-
cally affect HIV RNA transcription at the molecular level
[65], we assume that the survival probability of the P
stage, θ2, is reduced by a factor of exp(−hCt) in the pres-
ence of cytokine secreting CTLs. Here we again assume
a predator-prey relationship between cytokines and HIV
genes. The factor is depended on the levels of circulating
CTLs such that Ct → 0, exp(−hCt) → 1 and Ct →
∞, exp(−hCt) → 0.
CTLs release proteins (perforin and granzymes) that kill
infected cells [63]. The right hand side of equation (12)
is multiplied by exp(−h2Ct) to cater for the killing of
infected cells by CTLs. The killing of infected cells is
dependent on the levels of circulating CTLs.
Equation (13) models the dynamics of CTLs at time
t + 1. The function f (Tt), represents the proliferation
term for CTLs. Proliferation of CTLs is dependent on
CD4+ T cell density. The higher the density of CD4+ T
cells, the higher the proliferation for CTLs. We propose a
function of the form, f (Tt) = χa1Tt1+a1Tt , where χ is the prob-
ability that proliferation occurs. The interaction between
infected cells and the CTLs is modelled using a predator-
prey relationship. The proportion of infected cells that
have been preyed on is represented by 1 − exp(−h2Ct)
so that f (Tt)T∗t (1 − exp(−h2Ct)) gives the gain term of
CTLs due to interactions/contacts with infected cells. The
parameter μc is the proportion of CTLs that die naturally.
Death is also assumed to occur at the end of the time step.
The last equation models the dynamics of the antibod-
ies. The function g(Tt) = ψa2Tt1+a2Tt , represents proliferation
of B cells and ψ is the probability that proliferation occurs.
The proliferation term is dependent on the density of
helper T cells. The interaction between antibodies and
the virus is modelled using a predator-prey relationship.
The proportion of virus that have been preyed on is given
by 1 − exp(−h1Bt) so that the gain term of antibodies
is given by g(Tt)Vt (1 − exp(−h1Bt)). The parameter μB,
gives the proportion of B cells that die naturally per time
step. Death is assumed to occur at the end of the time step.
Model analysis
Boundedness of solutions
An important qualitative property of the discrete dynam-
ical system (7)-(14) relates to the boundedness and
positivity of solutions, since negative solutions do not
have biological meaning. We thus state the following
proposition.
Proposition 1. Solutions of the system of equations (7)-
(14) remain non-negative and are bounded whenever |ν +
a| < 1.
Proof. From equation (11) we have
Tt+1 ≤ (ν + a)Tt + ST .
The solution of
Tt+1 = (ν + a)Tt + ST
is given by
Tt = (ν + a)tT0 + ST
t−1∑
i=0




(ν + a)t is a geometric series we have
Tt =
{
(ν + a)tT0 + ST 1−(ν+a)t1−(ν+a) if (ν + a) = 1,
T0 + ST t if (ν + a) = 1.
This means that
Tt ≤ (ν+a)tT0 +ST 1 − (ν + a)
t
1 − (ν + a) for (ν+a) = 1. (15)
It can then be shown that
lim sup
t→∞
Tt ≤ ST1 − (ν + a) for |ν + a| < 1. (16)
From equation (10), it can be deduced that
T∗t+1 ≤
ST
1 − (ν + a) + (1 − μT∗)T
∗
t
Using the same procedure as above, we have
T∗t+1 ≤ (1−μT∗)tT∗0 +
ST
1 − (ν + a)
(
1 − (1 − μT∗)t
μT∗
)





(1 − (ν + a))μT∗ .









(1 − (ν + a))2μT∗ + (1 − μC)Ct
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is given by
Ct = (1−μC)tC0 + S
2
T
(1 − (ν + a))2μT∗
1 − (1 − μC)t
μC
.






(1 − (ν + a))2μT∗μC .






(1 − (ν + a))2μT∗μB .
The equations (7)-(10) for the virus at its different stages
can be given in matrix form as





0 0 0 β1 exp(−h1Bt)1+ωCt
θ1 θ3 0 0
0 θ2 exp(−hCt) θ3 0




















then n(t) ≤ n̄.





1+ωCt ≤ β1 exp(−h1Bt) ≤ β1, and




0 0 0 β1
θ1 θ3 0 0
0 θ2 θ3 0
0 0 θ2φ ST(1−(ν+a))μT∗ 0
⎞
⎟⎟⎟⎟⎟⎠ , then
N(t + 1) ≤ ĀN(t) + Bn̄,
where inequalities hold componentwise. The solution of
N(t + 1) = ĀN(t) + Bn̄ is given by N(t) = ĀtN(0) + (I −
Ā)−1(I − Āt)Bn̄ if Ā = I. This implies that




N(t) ≤ (I − Ā)−1Bn̄.
The system of equations (7)-(14) is thus bounded when-
ever |ν + a| < 1.
Disease free equilibrium point
The system of equations (7)-(14) has a disease free equi-
librium point given by
E0 =
(
0, 0, 0, 0, T̂ , 0, 0, 0
)
,
where T̂ = K(v+a−1)+K
√
(v+a−1)2+ 4aSTK
2a . The following
theorem is used to prove the stability of E0.
Theorem 2. Let Ē be a fixed point of the system of
equations (7)-(14).
• If all the eigenvalues of the Jacobian matrix of the
system of equations (7)-(14) evaluated at Ē, JĒ , have
moduli strictly less than 1, Ē is asymptotically stable.
• If at least one eigenvalue has modulus greater than 1,
then Ē is unstable.
• If no eigenvalue of JĒ is outside the unit circle but at
least one is on the boundary (has a modulus of 1), then
Ē, maybe stable, asymptotically stable or unstable.









)∣∣∣∣∣<1 and |(1−μT∗)+β2T̂| < 1.
Proof. The Jacobian matrix of the system of






, where J11 =
⎛
⎜⎜⎝
0 0 0 β1
θ1 θ3 0 0
0 θ2 θ3 0






0 β2 0 0
0 0 0 0
0 0 0 0
0 0 0 0
⎞
⎟⎟⎠ , J21 =
⎛
⎜⎜⎝
0 0 0 β1νT̂
0 0 0 β1T̂
0 0 0 0















0 1 − μT∗ + β2T̂ 0 0
0 0 1 − μC 0
0 0 0 1 − μB
⎞
⎟⎟⎟⎟⎟⎟⎠.









, 1 − μB, 1 − μC and (1 − μT∗) + β2KT̂ .
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| < 1 and |(1 − μT∗) + β2T̂ | < 1. Thus









| < 1 and |(1 − μT∗) + β2T̂ | < 1.
Endermic equilibrium point
Due to the complexity of the system of equations (7)-(14),
the conventional methods for finding the interior equi-
librium point fails, however, we can be guaranteed that
it exist by the theory of persistence and permanence of
discrete dynamical systems. Persistence conditions ensure
that no species will go extinct in a system of interacting
species whilst permanence conditions guarantees that the
size of each population is bounded and that each popula-
tion settles above certain threshold values. The following
are the definitions of persistence and permanence of the
system of equations (7)-(14).
Definition 4. [74]
1. The system of equations (7)-(14) is strongly
persistent at time τ if Dt , Pt , Qt , Vt , Tt , T∗t > 0 for
each t = 0, 1, 2, · · · τ .
2. The system of equations (7)-(14) is weakly persistent
at time τ if Dt , Pt , Qt , Vt , Tt , T∗t > 0 for each
t = 0, 1, 2, · · · τ − 1 and Dτ , Pt , Qτ , Vτ , T∗τ ≥ 0,
Dτ + Pt + Qτ + Vτ , > 0 and Tτ > 0.
3. The system of equations (7)-(14) is strongly persistent
if it is strongly persistent at time τ for τ = 0, 1, 2 · · ·
and lim supt→∞ Dt , Pt , Qt , Vt , Tt , T∗t > 0.
4. The system of equations (7)-(14) is uniformly
persistent if it is strongly persistent at time τ for
τ = 0, 1, 2 · · · and there exist a positive constant 

such that lim inft→∞ Dt , Pt , Qt , Vt , Tt , T∗t > 
 .
5. The system of equations (7)-(14) is permanent if it is
uniform persistent and point dissipative.
The following theorem will be used to study persistence
and permanence of the system of equations (7)-(14).
Theorem 5. [75] Let E be a locally compact space with
metric d and let X be a closed subset of E with nonempty
boundary Y and nonempty interior Ẋ. Suppose that f is a
continuous map on X with f (Y ) ⊂ Y and f (X\Y ) ⊂ X\Y .
Then f is uniformly persistent if the following hold
1. f is dissipative,
2. f |Y is isolated,
3. f |Y is acyclic,
4. for each Mi ∈ M, W+(Mi) ⋂ Ẋ = ∅.
Theorem 6. The system equations (7)-(14) is uniformly











)∣∣∣∣∣ > 1 and
|(1 − μT∗) + β2T̂| > 1.
Proof. Let E = Rn and X = R8+. The system of
equations (7-14) can be written as map defined as F :
R8+ → R8+ such that
F1(x) = β1V1 + ωC exp(−h1B) + β2T
∗,
F2(x) = θ1D + θ3P,
F3(x) = θ2 exp(−hC)P + θ3Q,
F4(x) = θ2φQT∗,
F5(x) = ST + νT exp
(
−βV exp(−h1B)
















1 + ωC − β2T
∗
)))
× exp(−h2C) + (1 − μT∗)T∗ exp(−h2C),
F7(x) = f (T)T∗ (1 − exp(−h2C)) + (1 − μC)C,
F8(x) = g(T)V (1 − exp(−h1B)) + (1 − μB)B,
where x = (D, P, Q, V , T , T∗, C, B).
Condition 1 of Theorem 5 holds by Proposition 1 above.
We now show condition 2. Define
C = {D, P, Q, V , T , T∗, C, B ∈ R8+ | D = P = Q = V = T∗
= C = B = 0}
and let Y = C. There is one constant solution M given
by D = P = Q = V = T∗ = C = B = 0 and







Dt , Pt , Qt , Vt , Tt , T∗t , Ct , Bt
)
is a solu-
tion of the system of equations emanating from C, then
by Proposition 3, limt→∞ Tt = T̂ . The set C is invariant
and isolated. Thus we can conclude that F|Y is isolated
and acyclic. To prove condition 4, we need to show that
W s(M)
⋂
R8+\Y = ∅. Suppose that W s(M)
⋂
R8+\Y =





Dt , Pt , Qt , Vt , Tt , T∗t , Ct , Bt
) = (0, 0, 0, 0, T̂ , 0, 0, 0).
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Let t0 be sufficiently large such that T̂ − ε < Tt < T̂ + ε
for ε sufficiently small and t > t0. For t > t0, we have
Dt+1 = β11 + ωCt exp(−h1Bt)Vt + β2T
∗
t , (17)
Pt+1 = θ1Dt + θ3Pt , (18)
Qt+1 = θ2 exp(−hCt)Pt + θ3Qt , (19)










× exp(−h2Ct) + (1 − μT∗)T∗t exp(−h2Ct),
(21)
Ct+1 ≥ f (m − ε)T∗t (1 − exp(−h2Ct)) + (1 − μC)Ct ,
(22)
Bt+1 ≥ g(m − ε)Vt (1 − exp(−h1Bt)) + (1 − μB)Bt .
(23)
Consider the system
D̄t+1 = β11 + ωC̄t
exp(−h1B̄t)V̄t + β2T̄∗t , (24)
P̄t+1 = θ1D̄t + θ3P̄t , (25)
Q̄t+1 = θ2 exp(−hC̄t)P̄t + θ3Qt , (26)
V̄t+1 = θ2φQ̄tT̄∗t , (27)









× exp(− h2Ct) + (1 − μT∗)T∗t exp (−h2Ct) ,
(28)
C̄t+1 = f (m − ε)T̄∗t
(
1 − exp(−h2C̄t)
) + (1 − μC)C̄t ,
(29)
B̄t+1 = g(m − ε)V̄t
(
1 − exp(−h1B̄t)
) + (1 − μB)B̄t .
(30)
The Jacobian matrix of the system of equations (24)-(30)









0 0 0 β1
θ1 θ3 0 0
0 θ2 θ3 0












⎝ 0 0 0 β1(m − ε)0 0 0 0
0 0 0 0
⎞
⎠ and J̄22 =
⎛
⎝ 1 − μ∗T 0 00 1 − μC 0
0 0 1 − μB
⎞
⎠.
J̄ is nonnegative and irreducible and thus it has an
eigenvalue that is greater than 1 and a corresponding
eigenvector which we denote by v. The trivial equilibrium
point is thus unstable. Next we choose any number l > 0,
that is small such that
lv1 < Dt0 , lv2 < Pt0 , lv3 < Qt0 , lv4 < Vt0 , lv5 < T∗t0 ,
lv6 < Ct0 , lv7 < Bt0 .
If
(
D̄t , P̄t , Q̄t , V̄t , T̄∗t , C̄t , B̄t
)
is a solution of the system
of equations (24)-(30) with lv1 = D̄t0 , lv2 = P̄t0 , lv3 =
Q̄t0 , lv4 = V̄t0 , lv5 = T̄∗t0 , lv6 = C̄t0 , lv7 = B̄t0 , then we
are guaranteed that
Dt ≥ D̄t , Pt ≥ P̄t , Qt ≥ Q̄t , Vt ≥ V̄t , T∗t ≥ T̄∗t , Ct ≥ C̄t ,
Bt ≥ B̄t .
From proposition 1 we have that
(
Dt , Pt , Qt , Vt , Tt , T∗t ,
Ct , Bt
)
are bounded. It can easily be shown that
the system of equations (24)-(30) is also bounded.
It follows from Lemma 5.2 in [74] that the map
defined by the system of equations (24)-(30) converge to
a unique equilibrium point
(
D̄∗, P̄∗, Q̄∗, V̄ ∗, T̄∗∗, C̄∗, B̄∗
)





Dt , Pt ,Qt , Vt , T∗t , Ct , Bt
)≥(D̄∗, P̄∗, Q̄∗, V̄ ∗, T̄∗∗, C̄∗, B̄∗)
> (0, 0, 0, 0, 0, 0, 0),
componentwise. This contradicts the assumption that
limt→∞(Dt , Pt , Qt ,Vt , T∗t ,Ct , Bt)=(0, 0, 0, 0, 0, 0, 0). Hence
W s(M)
⋂
R8+\Y =∅. Thus the system of equation (7)-(14)
is uniformly persistent.
Proposition 7. The system of equations (7)-(14) is
permanent.
Proof. The result follows from definition 1.5.
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Additional file 1: The first section of the file gives the elasticity
analysis of the viral levels to HIV life cycle parameters. The general
trend that was observed was that the viral levels were more elastic to
parameters of the late stages of the life cycle (φ, θ2) than parameters of
the early stages of the viral life cycle (β1, θ1). Targeting the late stages of
the HIV life cycle results in lower viral levels than targeting the early stages.
The second section of the file deals with finding the form of transmission
that is more efficient in vivo between cell free and cell associated
transmission using mathematical models. The model results showed that
cell-associated transmission is more efficient in transmitting the infection
than cell-free transmission in the blood.
Additional file 2: The first section of the file gives the derivation of
the elasticities of the viral levels to immune response parameters
formulae and the last section shows how the Negative Binomial
Distribution was used to approximate the provirus stage duration.
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